A long-acting GLP-1 receptor agonist with potential for biweekly dosing developed by Sciwind Biosciences.
Ecnoglutide (XW003) is an investigational long-acting GLP-1 receptor agonist originally developed by Sciwind Biosciences and licensed to Merck (as MK-6024). Its key differentiator is an extended half-life that may enable biweekly (every 2 weeks) dosing — reducing injection frequency compared to weekly semaglutide or tirzepatide.
The extended duration of action is achieved through structural modifications including Fc fusion or albumin binding that extend the peptide's circulation time. Less frequent dosing could improve patient adherence and quality of life compared to weekly injections.
Ecnoglutide is in Phase 2 clinical trials for obesity and type 2 diabetes. Merck's licensing agreement suggests significant commercial interest in the biweekly dosing advantage.
Phase 1/2 data showed dose-dependent weight loss and favorable metabolic improvements consistent with GLP-1 receptor agonism. The biweekly dosing schedule was feasible with maintained efficacy between doses.
Competitive positioning in the crowded GLP-1 landscape depends on demonstrating comparable efficacy to weekly agents with the convenience of less frequent dosing. Phase 2 dose-ranging studies are ongoing.
GI side effects typical of GLP-1 class. Extended half-life means side effects, if they occur, may persist longer. Full safety profile pending. Clinical trial use only.
NOT FDA-approved. In Phase 2 clinical trials. Licensed to Merck.